Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v6-EN Version v6-EN
Language English English
Date Updated 2021-04-16 2021-04-16
Drug Identification Number 02439409 02439409
Brand name ROPIVACAINE HYDROCHLORIDE INJECTION, USP ROPIVACAINE HYDROCHLORIDE INJECTION, USP
Common or Proper name Ropivacaine Hydrochloride Injection, USP 10 mg/mL Ampoule 20 mL Ropivacaine Hydrochloride Injection, USP 10 mg/mL Ampoule 20 mL
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients ROPIVACAINE HYDROCHLORIDE ROPIVACAINE HYDROCHLORIDE
Strength(s) 10MG 10MG
Dosage form(s) SOLUTION SOLUTION
Route of administration EPIDURAL EPIDURAL EPIDURAL EPIDURAL
Packaging size 20 mL 20 mL
ATC code N01BB N01BB
ATC description ANESTHETICS, LOCAL ANESTHETICS, LOCAL
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2021-03-26 2021-03-26
Actual start date 2021-03-26 2021-03-26
Estimated end date 2021-04-30 2021-04-30
Actual end date 2021-04-15 2021-04-15
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments Fresenius Kabi Canada Ltd. is pleased to advise that the backorder on Ropivacaine Hydrochloride Injection, USP has been resolved earlier than anticipated and the product is now available across all distribution centers. Fresenius Kabi Canada Ltd. is pleased to advise that the backorder on Ropivacaine Hydrochloride Injection, USP has been resolved earlier than anticipated and the product is now available across all distribution centers.
Health Canada comments